AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00954122
- Locations
- 🇲🇾
Research Site, Kuala Lumpur, Malaysia
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 74
- Registration Number
- NCT00952588
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 203
- Registration Number
- NCT00953888
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Study of Multiple Doses of Saxagliptin (BMS-477118)
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 423
- Registration Number
- NCT00950599
A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: AZD9668 Placebo
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 838
- Registration Number
- NCT00949975
- Locations
- 🇺🇦
Research Site, Lugansk, Ukraine
Symbicort SMART Satisfaction From Patient Perspective 2009
Completed
- Conditions
- Asthma
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2010-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 205
- Registration Number
- NCT00946452
- Locations
- 🇲🇾
Research Site, Petaling Jaya, Selangor, Malaysia
AZD7325 Japan Multiple Ascending Dose (MAD) Study
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2011-02-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00945425
Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers
Phase 1
Terminated
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT00945178
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
Phase 3
Completed
- Conditions
- Progression-free Survival
- Interventions
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT00944918
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension
Completed
- Conditions
- Hypertension
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1150
- Registration Number
- NCT00944489
- Locations
- 🇦🇷
Research Site, Buenos Aires, Argentina